Kenvue Inc.

KVUE Consumer Defensive Household & Personal Products

Kenvue Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.1 billion, down 2.14% from fiscal 2024. In the quarter to June 2026, revenue grew 3.02%, EPS grew 9.09%, free cash flow grew 17.1% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years; insiders bought in the last twelve months.

17.61 0.22 −1.23%
Market cap
$34.3B
P/E
20.5×
Fwd P/E
18.6×
Dividend yield
5.85%
F-score
5/9
Altman Z
2.05
Beneish M
−2.47
Dividend safety
24/100

Kenvue Inc. 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 28, 2025 · Filed · accepted 7:13 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 24, 2025: 1 added · 59 modified

  1. Modified · Company Overview

    At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.515.1 billion in Net sales in the fiscal year 20242025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including TylenolAveeno®, NeutrogenaBAND-AID®, Listerine® Brand, Johnson’s®, BAND-AIDListerine® Brand, Neutrogena®, AveenoNicorette®, ZyrtecTylenol®, and NicoretteZyrtec®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands.

59 more changes in this Item, word by word, in Powerpack.

Powerpack